(Q42595787)
Statements
1 reference
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results (English)
1 reference
1 reference
G Giovannoni
1 reference
F Casset-Semanaz
1 reference
J King
1 reference
L Metz
1 reference
J Simsarian
1 reference
P S Sørensen
1 reference
B Stubinski
1 reference
28 August 2008
1 reference
1 reference
15
1 reference
2
1 reference
219-228
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference